Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Assay Kit

PEDV Spike glycoprotein (RBD) ELISA Kit

Catalog #:   KVV31301 Specific References (37) DATASHEET
Sample type: Plasma, Serum
Sensitivity: 0.65 ng/mL
Range: 1.56 - 100 ng/mL
Overview

Catalog No.

KVV31301

Specificity

PEDV Spike glycoprotein (RBD)

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

1.56 - 100 ng/mL

Sensitivity

0.65 ng/mL

Precision

CV<15%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Data Image
References

Designed miniproteins potently inhibit and protect against MERS-CoV., PMID:40450691

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories., PMID:39772242

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV., PMID:39644492

Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses., PMID:39488210

A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification., PMID:39383863

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals., PMID:39197450

Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans., PMID:39058596

Human coronavirus HKU1 recognition of the TMPRSS2 host receptor., PMID:38964328

Spike deep mutational scanning helps predict success of SARS-CoV-2 clades., PMID:38961298

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission., PMID:38953636

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines., PMID:38944664

Evidences support that dengue virus can impart broad-spectrum immunity against betacoronaviruses in dengue endemic regions., PMID:38932494

The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study., PMID:38921803

Murine alveolar macrophages rapidly accumulate intranasally administered SARS-CoV-2 Spike protein leading to neutrophil recruitment and damage., PMID:38507462

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans., PMID:38490197

Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity., PMID:38459086

Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus., PMID:37989312

Neutralization, effector function and immune imprinting of Omicron variants., PMID:37648855

Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics., PMID:36503013

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice., PMID:35988541

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern., PMID:35695453

A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike., PMID:35273217

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy., PMID:35134084

ACE2 binding is an ancestral and evolvable trait of sarbecoviruses., PMID:35114688

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines., PMID:34619077

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models., PMID:34547465

Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design., PMID:34267764

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape., PMID:34261126

SARS-CoV-2 Variants and Vaccines., PMID:34161052

Tackling COVID-19 with neutralizing monoclonal antibodies., PMID:34087172

Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein., PMID:33909660

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2., PMID:33761326

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies., PMID:33706364

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2., PMID:33160446

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection., PMID:33139569

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies., PMID:32375025

A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated Salmonella induces serum and secretory immunity., PMID:8725098

Datasheet
$ 1128
Product specifications
96 T 1128

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

PEDV Spike glycoprotein (RBD) ELISA Kit [KVV31301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only